Healthy volunteers test new lung fibrosis drug combo safety
NCT ID NCT07229716
First seen Nov 17, 2025 · Last updated May 25, 2026 · Updated 29 times
Summary
This study tests how a new experimental drug (HRS-9813) interacts with two approved medicines for pulmonary fibrosis (pirfenidone and nintedanib) in 20 healthy adults aged 18-45. The goal is to measure drug levels in the blood and check for side effects, helping to guide future dosing. Participants must be healthy, not smoke, and avoid certain medications during the trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, Fourth Military Medical University
RECRUITINGXi’an, Shanxi, 710026, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.